Zhenqi Huang
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group.
Journal: American journal of hematology
Published: December 12, 2025
Correction: Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.
Journal: Cancer cell international
Published: October 28, 2025
Efficacy and Long-term Prognosis of Flumatinib in the Treatment of Chronic Myelocytic Leukemia
Journal: Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
Published: September 28, 2025
Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.
Journal: Cancer cell international
Published: November 01, 2024
Safety and Efficacy of Low-Dose Venetoclax Plus Voriconazole in Patients With Acute Myeloid Leukemia Unfit for Intensive Chemotherapy.
Journal: Hematological oncology
Published: October 15, 2024
SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients.
Journal: Current gene therapy
Published: February 21, 2023
TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes.
Journal: Frontiers in oncology
Published: February 19, 2022
Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
Journal: Frontiers in immunology
Published: May 09, 2021
Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib.
Journal: Cancer management and research
Published: March 10, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026